RECRUITING

Targeted Oligometastatic Radiation in Pediatric and Young Adult Patients With Soft Tissue and Bone Sarcoma

Talk to us

Conditions

Metastatic SarcomaRadiation Therapy PatientEwing SarcomaRhabdomyosarcomaPediatricBrain tumorLongitudinalRadiation Therapy

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This study is designed for children, adolescents and young adults undergoing radiation therapy for metastatic sarcoma. The aim of the study is to investigate if the investigators can improve the overall survival of these patients by targeting metastatic sites with radiation.

Official Title

Targeted Oligometastatic Radiation in Pediatric and Young Adult Patients With Soft Tissue and Bone Sarcoma

Quick Facts

Study Start:2025-03
Study Completion:2030-03
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06796543

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:Not specified to 39 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:CHILD, ADULT
Inclusion CriteriaExclusion Criteria
  1. * Patients must be aged \< 39 years at time of enrollment.
  2. * Patients must have a Karnofsky or Lansky performance score of 70 or greater or Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
  3. * Patients must have newly diagnosed histologically or molecularly confirmed soft tissue or bone sarcoma at any site.
  4. * Patients must have metastatic disease that is measurable and this is defined as at least one lesion discontinuous from the primary that can be accurately measured in at least one dimension (longest diameter to be recorded) as \> 3mm with CT scan within 3 weeks from treatment start.
  1. * Brain or intracranial metastases, including leptomeningeal disease
  2. * Clinical or radiologic evidence of spinal cord compression requiring emergent radiation treatment
  3. * Positive bone marrow biopsy for non-pelvic primary and greater than eight bone metastases. Presence of parenchymal lung metastases is considered as one metastasis, irrespective of how many lung nodules are present.
  4. * Evidence of any non-measurable metastatic disease including but not limited to leptomeningeal disease, malignant ascites and malignant pleural or pericardial effusions.
  5. * Pregnancy

Contacts and Locations

Study Contact

Sahaja Acharya, MD
CONTACT
4432877889
sachary7@jhmi.edu
Ethan Arnone, BS
CONTACT
2029192533
earnone3@jh.edu

Principal Investigator

Sahaja Acharya, MD
PRINCIPAL_INVESTIGATOR
SKCCC Johns Hopkins Medical Institution

Study Locations (Sites)

Sibley Memorial Hospital
Washington, District of Columbia, 20016
United States
Johns Hopkins Hospital
Baltimore, Maryland, 21287
United States

Collaborators and Investigators

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

  • Sahaja Acharya, MD, PRINCIPAL_INVESTIGATOR, SKCCC Johns Hopkins Medical Institution

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-03
Study Completion Date2030-03

Study Record Updates

Study Start Date2025-03
Study Completion Date2030-03

Terms related to this study

Keywords Provided by Researchers

  • Pediatric
  • Metastatic Sarcoma
  • Ewing sarcoma
  • Rhabdomyosarcoma
  • Brain tumor
  • Longitudinal
  • Radiation Therapy

Additional Relevant MeSH Terms

  • Metastatic Sarcoma
  • Radiation Therapy Patient
  • Ewing Sarcoma
  • Rhabdomyosarcoma